The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs
about
Cytomegalovirus antivirals and development of improved animal modelsCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsDevelopment of a guinea pig immune response-related microarray and its use to define the host response following Mycobacterium bovis BCG vaccinationCloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication.Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.Main adult herpes virus infections of the CNS.Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission.Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.How we treat cytomegalovirus in hematopoietic cell transplant recipients.Genome Sequence of a Novel, Newly Identified Isolate of Guinea Pig Cytomegalovirus, the CIDMTR Strain.Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.Nonimmune hydrops fetalis and fulminant fatal disease due to congenital cytomegalovirus infection in a premature infant.
P2860
Q27000998-F81C8ADC-97F0-4EEB-BDBC-5C294C63DE78Q27023452-EE949313-5864-4B99-BD36-CF92FD18817AQ30231394-CDA9989E-97B1-47AB-8CA5-0EF6489087CDQ33702995-E7A86008-BC9E-44EE-8070-86D47FE42EF6Q36080805-62EE620A-363A-47DC-B7FA-971453FABAE5Q36233543-D33304BB-6645-414C-8C3B-98A664F16458Q36517126-DEC71847-7555-4F6E-8432-D6D737334C1FQ37182699-025962B0-73F5-416C-8DDE-E7CB1A680AB5Q37237427-3B42E60A-1D73-41A8-8EDD-07F286FF13A6Q37415756-6A6BE1D5-10B9-4C2B-827A-69D1F7493735Q37453329-FC9A12FD-A64D-4B79-92A0-B6DFB5CA68F9Q37611802-B9FBBF81-DD10-4CF7-8DE5-E9EAD1C6213AQ37951633-01D55067-2A42-4243-9A40-549F1E2F64AAQ39325580-D825DFFB-334B-443E-AE70-A5601D003120Q40076090-65A930DB-E943-4F00-AA03-BB141F57A350Q44923353-C395157F-946F-4A9F-8007-DBFBB3AA8014
P2860
The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The non-nucleoside antiviral, ...... immunocompromised guinea pigs
@en
The non-nucleoside antiviral, ...... immunocompromised guinea pigs.
@nl
type
label
The non-nucleoside antiviral, ...... immunocompromised guinea pigs
@en
The non-nucleoside antiviral, ...... immunocompromised guinea pigs.
@nl
prefLabel
The non-nucleoside antiviral, ...... immunocompromised guinea pigs
@en
The non-nucleoside antiviral, ...... immunocompromised guinea pigs.
@nl
P2093
P2860
P1433
P1476
The non-nucleoside antiviral, ...... immunocompromised guinea pigs
@en
P2093
Alistair McGregor
Blaine Creasy
David I Bernstein
Fernando Bravo
Greg Stroup
Kristin Henninger
Mark R Schleiss
Michael A McVoy
Sabine Hallenberger
P2860
P356
10.1016/J.ANTIVIRAL.2004.09.004
P577
2005-01-01T00:00:00Z